Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Myvac

Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update

2026 Q3

Published 9 November 2026
Categorized as 2025, 2026, 2026, dates, Myvac, Press release

Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field

2026 Half Year results

Published 24 September 2026
Categorized as 2025, 2026, 2026, dates, Myvac, Press release

Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line

ProBioGen

Published 8 September 2026
Categorized as 2025, 2026, 2026, dates, Myvac, Press release

A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial

C. Ottensmeier, et al. Article available on Nature Communications website – Download the Article

Published 2 September 2026
Categorized as 2026, Myvac, Publication, publication key en, TG4050

Transgene expands myvac®into NSCLC with TG4070

link to webcast

Published 29 June 2026
Categorized as 2026, Myvac, TG4070, Webcast, Webcast

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine

TG4070

Published 22 June 2026
Categorized as 2025, 2025, 2026, 2026, dates, Myvac, Press release

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

TG4050

Published 13 April 2026
Categorized as 2025, 2025, 2026, 2026, Myvac, Press release, TG4050

TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment

K. Bidet-Huang World Vaccine Congress 2026 – Download the Oral Presentation

Published 1 April 2026
Categorized as 2026, Myvac, Publication, publication key en, TG4050

2025 Full-year results and business update

link to webcast

Published 24 March 2026
Categorized as 2025, Myvac, TG4050, Webcast, Webcast

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

medRxiv 2026

Published 9 January 2026
Categorized as 2026, Myvac, Press release, TG4050

Posts pagination

Page 1 … Page 7 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu